Liver Function in Pediatric Recipients: A Comparison of Intralipid and Smoflipid
JournalJournal of pediatric pharmacology and therapeutics
PublisherPediatric Pharmacy Advocacy Group, Inc.
MetadataShow full item record
AbstractOBJECTIVES An adverse consequence of primarily soybean oil–based parenteral nutrition is the development of intestinal failure–associated liver disease (IFALD), defined as bilirubin ≥ 2 mg/dL. Fish oil– containing lipid emulsion products, such as soybean oil, medium-chain triglycerides, olive oil, fish oil lipid injectable emulsion (SMOF-ILE), have been shown to be beneficial in patients at risk of developing IFALD. This study aimed to review the safety profile of SMOF-ILE and soybean oil–based lipid injectable emulsion (SO-ILE) in regard to liver function and cholestasis in the pediatric and neonatal population. METHODS A retrospective review was performed for patients who received SO-ILE or SMOF-ILE over a 3-year period. Patients < 18 years of age who received at least 2 weeks of either product were included. The primary endpoints were 2 consecutive bilirubin readings ≥ 2 mg/dL that were separated by at least 1 week and time to first bilirubin ≥ 2 mg/dL. Secondary endpoints included assessment of select laboratory values (i.e., aspartate aminotransferase, alanine aminotransferase, triglycerides, serum creatinine, serum sodium, coagulation laboratory test, albumin) up to 6 months while on intravenous lipid products. Ursodiol use and mortality were also noted. RESULTS There was a higher prevalence of IFALD in pediatric patients receiving SO-ILE than those who received SMOF-ILE (32% vs 12%, p = 0.03). There was no detectable difference in the time it took for IFALD to develop (19 days vs 15 days, p = 0.08). CONCLUSION In our cohort of pediatric and neonatal patients, the incidence of IFALD was higher with SOILE than with SMOF-ILE. ABBREVIATIONS ALT, alanine aminotransferase, AST, aspartate aminotransferase, EFAD, essential fatty acid deficiency, FDA, US Food and Drug Administration, GI, gastrointestinal, IFALD, intestinal failure–associated liver disease, ILEs, lipid injectable emulsions, INR, international normalized ratio, NICU, neonatal intensive care unit, PN, parenteral nutrition, SMOF-ILE, soybean oil, medium-chain triglycerides, olive oil, fish oil lipid injectable emulsion, SO-ILE, soybean oil–based lipid injectable emulsion. © Pediatric Pharmacy Association. All rights reserved.
Rights/TermsCopyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: email@example.com 2021.
intestinal failure–associated liver disease
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15560
- Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid)--a double-blind, randomised, multicentre study in adults.
- Authors: Klek S, Chambrier C, Singer P, Rubin M, Bowling T, Staun M, Joly F, Rasmussen H, Strauss BJ, Wanten G, Smith R, Abraham A, Szczepanek K, Shaffer J
- Issue date: 2013 Apr
- SMOFlipid vs Intralipid 20%: Effect of Mixed-Oil vs Soybean-Oil Emulsion on Parenteral Nutrition-Associated Cholestasis in the Neonatal Population.
- Authors: Jackson RL, White PZ, Zalla J
- Issue date: 2021 Feb
- Reversal of Intestinal Failure-Associated Liver Disease by Switching From a Combination Lipid Emulsion Containing Fish Oil to Fish Oil Monotherapy.
- Authors: Lee S, Park HJ, Yoon J, Hong SH, Oh CY, Lee SK, Seo JM
- Issue date: 2016 Mar
- Development of Parenteral Nutrition-Associated Liver Disease and Other Adverse Effects in Neonates Receiving SMOFlipid or Intralipid.
- Authors: Stramara L, Hernandez L, Bloom BT, Durham C
- Issue date: 2020 Nov
- Reversal of Intestinal Failure-Associated Liver Disease by Increasing Fish Oil in a Multi-Oil Intravenous Lipid Emulsion in Adult Short Bowel-Syndrome Patients.
- Authors: Park HJ, Lee S, Park CM, Yoo K, Seo JM
- Issue date: 2021 Jan